摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-((4-fluorophenoxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(4-fluorophenyl)methanone | 1384873-39-5

中文名称
——
中文别名
——
英文名称
(3-((4-fluorophenoxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(4-fluorophenyl)methanone
英文别名
[3-[(4-fluorophenoxy)methyl]-7,8-dihydro-5H-1,6-naphthyridin-6-yl]-(4-fluorophenyl)methanone
(3-((4-fluorophenoxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(4-fluorophenyl)methanone化学式
CAS
1384873-39-5
化学式
C22H18F2N2O2
mdl
——
分子量
380.394
InChiKey
LOMPCLUTYIJQDZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    28
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    42.4
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为产物:
    描述:
    3-溴咪唑[1,2-A] 5,6,7,8-四氢-1,6-萘啶盐酸盐 在 sodium tetrahydroborate 、 四(三苯基膦)钯偶氮二甲酸二异丙酯臭氧N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下, 以 四氢呋喃甲醇二氯甲烷N,N-二甲基甲酰胺丙酮甲苯 为溶剂, 反应 2.08h, 生成 (3-((4-fluorophenoxy)methyl)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)(4-fluorophenyl)methanone
    参考文献:
    名称:
    Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu5)
    摘要:
    Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu(5)) represent a promising therapeutic strategy for the treatment of schizophrenia. Starting from an acetylene-based lead from high throughput screening, an evolved bicyclic dihydronaphthyridinone was identified. We describe further refinements leading to both dihydronaphthyridinone and tetrahydronaphthyridine mGlu(5) PAMs containing an alkoxy-based linkage as an acetylene replacement. Exploration of several structural features including western pyridine ring isomers, positional amides, linker connectivity/position, and combinations thereof, reveal that these bicyclic modulators generally exhibit steep SAR and within specific subseries display a propensity for pharmacological mode switching at mGlu(5) as well as antagonist activity at mGlu(3). Structure-activity relationships within a dihydronaphthyridinone subseries uncovered 12c (VU0405372), a selective mGlu(5) PAM with good in vitro potency, low glutamate fold-shift, acceptable DMPK properties, and in vivo efficacy in an amphetamine-based model of psychosis.
    DOI:
    10.1021/jm500259z
点击查看最新优质反应信息

文献信息

  • DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS
    申请人:Conn P. Jeffrey
    公开号:US20120178776A1
    公开(公告)日:2012-07-12
    In one aspect, the invention relates to dihydronaphthyridinyl(organo)methanone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    在一方面,该发明涉及二氢萘啉基(有机)甲酮类似物、其衍生物和相关化合物,这些化合物可用作代谢型谷氨酸受体亚型5 (mGluR5)的正向变构调节剂;制备这些化合物的合成方法;包含这些化合物的药物组合物;以及使用这些化合物和组合物治疗与谷氨酸功能障碍相关的神经和精神疾病的方法。本摘要旨在作为在特定领域搜索的扫描工具,并不限制本发明。
  • US8710074B2
    申请人:——
    公开号:US8710074B2
    公开(公告)日:2014-04-29
  • [EN] DIHYDRONAPHTHYRIDINYL(ORGANO)METHANONE ANALOGS AS POSITIVE ALLOSTERIC MGLUR5 MODULATORS<br/>[FR] ANALOGUES DE DIHYDRONAPHTYRIDINYL-(ORGANO)MÉTHANONE UTILISABLES COMME MODULATEURS ALLOSTÉRIQUES POSITIFS DE MGLUR5
    申请人:UNIV VANDERBILT
    公开号:WO2012097182A1
    公开(公告)日:2012-07-19
    In one aspect, the invention relates to dihydronaphthyridinyl(organo)methanone analogs, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
  • Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu<sub>5</sub>)
    作者:Mark Turlington、Chrysa Malosh、Jon Jacobs、Jason T. Manka、Meredith J. Noetzel、Paige N. Vinson、Satyawan Jadhav、Elizabeth J. Herman、Hilde Lavreysen、Claire Mackie、José M. Bartolomé-Nebreda、Susana Conde-Ceide、M. Luz Martín-Martín、Han Min Tong、Silvia López、Gregor J. MacDonald、Thomas Steckler、J. Scott Daniels、C. David Weaver、Colleen M. Niswender、Carrie K. Jones、P. Jeffrey Conn、Craig W. Lindsley、Shaun R. Stauffer
    DOI:10.1021/jm500259z
    日期:2014.7.10
    Positive allosteric modulators (PAMs) of metabotropic glutamate receptor 5 (mGlu(5)) represent a promising therapeutic strategy for the treatment of schizophrenia. Starting from an acetylene-based lead from high throughput screening, an evolved bicyclic dihydronaphthyridinone was identified. We describe further refinements leading to both dihydronaphthyridinone and tetrahydronaphthyridine mGlu(5) PAMs containing an alkoxy-based linkage as an acetylene replacement. Exploration of several structural features including western pyridine ring isomers, positional amides, linker connectivity/position, and combinations thereof, reveal that these bicyclic modulators generally exhibit steep SAR and within specific subseries display a propensity for pharmacological mode switching at mGlu(5) as well as antagonist activity at mGlu(3). Structure-activity relationships within a dihydronaphthyridinone subseries uncovered 12c (VU0405372), a selective mGlu(5) PAM with good in vitro potency, low glutamate fold-shift, acceptable DMPK properties, and in vivo efficacy in an amphetamine-based model of psychosis.
查看更多